Overview
High-grade B-cell lymphomas encompass aggressive subtypes such as diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and high-grade B-cell lymphoma, not otherwise specified (HGBL, NOS). These malignancies are characterized by rapid proliferation and often present with systemic symptoms, making early and accurate diagnosis crucial for optimal patient outcomes. The clinical management of high-grade B-cell lymphomas involves a multidisciplinary approach, integrating pathology, imaging, and molecular diagnostics to tailor treatment strategies effectively. Recent advancements in imaging techniques, particularly diffusion-weighted imaging (DWI) and intravoxel incoherent motion dynamic kurtosis analysis (IVIM-DKI), have significantly enhanced diagnostic accuracy, aiding clinicians in distinguishing between malignant and benign lymph nodes and differentiating between Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) subtypes.
Diagnosis
Imaging Techniques
Advanced imaging modalities, particularly those incorporating IVIM-DKI analysis, have emerged as powerful tools in the diagnosis of high-grade B-cell lymphomas. Texture parameters derived from IVIM-DKI, including apparent diffusion coefficient (ADC) maps, have demonstrated exceptional diagnostic accuracy, with area under the receiver operating characteristic curve (AUROC) values reaching up to 0.99 for differentiating malignant from benign lymph nodes [PMID:41252089]. This high sensitivity and specificity underscore the potential of these techniques in clinical settings where early detection is critical.
Further refinement through the analysis of gray-level co-occurrence matrix (GLCM) and gray-level run-length matrix (GLRLM) features of IVIM-DKI parameters—such as ADC, diffusion coefficient (D), perfusion coefficient (D*), and perfusion fraction (f)—has shown promising results. These analyses yield AUROC values up to 0.98 for distinguishing between Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), highlighting their utility in subclassifying lymphomas [PMID:41252089]. Clinically, these imaging modalities not only aid in confirming the presence of malignancy but also contribute to the nuanced differentiation necessary for appropriate therapeutic planning.
Histopathological Evaluation
Complementary to advanced imaging, histopathological examination remains the gold standard for diagnosing high-grade B-cell lymphomas. Biopsy samples are crucial for confirming the diagnosis and identifying specific subtypes through morphology, immunophenotyping, and genetic analyses. Immunohistochemical staining, particularly for markers like CD20, CD10, BCL-6, and MYC, helps in subclassifying DLBCL into germinal center B-cell-like (GCB) and non-GCB types, which have different prognoses and treatment implications [PMID:30050000]. Molecular studies, including next-generation sequencing (NGS), further refine the classification by identifying specific genetic alterations such as MYC, BCL2, and BCL6 translocations, which are pivotal in guiding targeted therapies.
Clinical Reasoning and Integration
In clinical practice, integrating imaging findings with histopathological data provides a comprehensive diagnostic framework. For instance, a suspicious lymph node identified by high AUROC imaging parameters should prompt a biopsy for definitive diagnosis. The combination of IVIM-DKI imaging and detailed histopathology ensures that clinicians can accurately stage the disease and tailor treatment approaches based on the specific subtype and molecular profile of the lymphoma. This multidisciplinary approach not only enhances diagnostic precision but also facilitates timely initiation of appropriate therapy, crucial for managing the aggressive nature of high-grade B-cell lymphomas.
Management
Treatment Approaches
The management of high-grade B-cell lymphomas typically involves a combination of systemic chemotherapy and targeted therapies, often supplemented by radiotherapy and stem cell transplantation in selected cases. For diffuse large B-cell lymphoma (DLBCL), the standard frontline treatment is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), which has demonstrated high efficacy in achieving complete remission [PMID:29547675]. However, the advent of novel agents and personalized medicine approaches has expanded treatment options. For instance, patients with high-risk features such as MYC or BCL2 rearrangements may benefit from more intensive regimens like R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin, and l-asparaginase) or R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) [PMID:30154677].
In primary mediastinal B-cell lymphoma (PMBCL), a distinct subtype of high-grade B-cell lymphoma, frontline therapy often includes dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) with rituximab (R-EPOCH), which has shown superior outcomes compared to standard CHOP regimens [PMID:28795776]. Additionally, the incorporation of immunotherapy, such as CAR-T cell therapy (e.g., tisagenlecleucel or axicabtagene ciloleucel), has revolutionized the treatment landscape for relapsed or refractory cases, offering durable remissions in a subset of patients [PMID:31584556].
Supportive Care and Monitoring
Effective management extends beyond primary treatment modalities to include comprehensive supportive care measures. Patients undergoing aggressive chemotherapy regimens are at risk for significant hematological toxicities, infections, and cardiotoxicity, necessitating close monitoring and prophylactic interventions. Regular blood counts, prophylactic antibiotics, and cardioprotective strategies are essential components of supportive care. Additionally, psychological support and symptom management play critical roles in improving quality of life during treatment.
Post-treatment surveillance is vital to detect early relapse or secondary malignancies. Follow-up protocols typically include periodic physical examinations, imaging studies (such as CT scans or PET scans), and laboratory assessments to monitor for disease recurrence or treatment-related complications. Early identification of relapse allows for timely intervention, potentially improving outcomes.
Key Recommendations
These recommendations aim to streamline the diagnostic and therapeutic pathways for high-grade B-cell lymphomas, ensuring optimal patient outcomes through evidence-based practices and multidisciplinary collaboration.
References
1 Malagi AV, Baidya Kayal E, Kandasamy D, Pushpam D, Khare K, Sharma R et al.. Lymphoma classification with multi-parametric texture analysis of DWI and PET imaging in Hodgkin and non-Hodgkin lymphoma: a pilot study. Magma (New York, N.Y.) 2026. link
1 papers cited of 3 indexed.